Table 1 Demographic data at diagnosis and follow-up in hypertensive children with controlled and uncontrolled HT assessed by ABPM

At diagnosis

Age, y (mean ± SD)

11.5 ± 4.14

11.17 ± 4.59

11.7 ± 3.91

0.52

Male, N (%)

70 (64.8)

24 (66.7)

46 (63.9)

0.83

BMI z-score, median (IQR)

1.13

2.11

0.64

0.06

(-0.43, 2.58)

(0.28, 2.76)

(-0.56, 2.5)

Office SBP index, median (IQR)

1.04 (1, 1.09)

1.04 (1.01, 1.09)

1.03 (1, 1.09)

0.59

Office DBP index, median (IQR)

1 (0.91, 1.08)

1 (0.91, 1.09)

1 (0.92, 1.07)

0.61

Diagnosis by ABPM, N (%)

21 (19.4)

11 (15.3%)

11 (27.8)

0.13

Classification of HT

 - Primary HT (%)

56 (51.85)

25 (69.44)

31 (43.06)

0.006*

 - Kidney (%)

44 (40.74)

7 (19.44)

37 (51.39)

 - Non-kidney (%)

8 (7.41)

4 (11.11)

4 (5.56)

eGFR (ml/min/1.73m²), mean ± SD

91.1 ± 50.47

104.15 ± 42.3

84.38 ± 53.24

0.03*

At Follow-up

Age, y (mean ± SD)

14.25 ± 3.81

13.73 ± 3.87

14.5 ± 3.79

0.33

The 1st ABPM after treating HT (y), median (IQR)

1.8 (0.7, 3.7)

2.15 (0.7, 3.5)

1.7 (0.7, 3.9)

0.84

BMI z score, mean ± SD

1.08 ± 1.86

1.54 ± 1.44

0.84 ± 2

0.039*

BMI z score change, median (IQR)

0

-0.22

0.01

0.62

(-0.54, 0.47)

(-0.58, 0.42)

(-0.52, 0.56)

24-hr ABPM SBP index, mean ± SD

0.99 ± 0.08

0.92 ± 0.04

1.04 ± 0.07

< 0.001

24-hr ABPM DBP index,

0.93

0.85

0.97

< 0.001

median (IQR)

(0.86, 1)

(0.82, 0.9)

(0.92, 1.05)

eGFR (ml/min/1.73m²), median (IQR)

N = 101

N = 30

N = 71

0.59

98.02

97.63

98.17

(69.29, 119.26)

(85.45, 114.83)

(63.61, 121.76)

eGFR change (ml/min/1.73m²), median (IQR)

N = 97

N = 30

N = 67

0.014*

-0.23

-12.03

5.13

(-31.21, 18.98)

(-33.13, 9.74)

(-14.44, 35.66)

Number of anti-HT drugs per patient, mean ± SD

1.47 ± 0.66

1.48 ± 0.64

1.46 ± 0.67

0.89

Proteinuria, N (%)

N = 40

N = 6

N = 34

0.011*

19 (47.5)

0 (0)

19 (55.9)

ACEI monotherapy, N

13

6

7

0.11

ARB monotherapy, N

2

2

0

0.023*

CCB monotherapy, N

37

8

29

0.11